Application of hematoporphyrin derivative and laser‐induced photodynamical reaction in the treatment of lung cancer: A preliminary report on 21 cases

Li, Jun‐Heng; Zhao, Shu‐De; Song, Shou-Zhong; Chen, Yuping; Zhang, Li‐Tian

doi:10.1002/lsm.1900040105

Cited by 20 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete response was observed in 70% of lesions, and 48% of patients required subsequent surgery for incomplete response, recurrence, or second primary (44). A number of other studies have demonstrated similar pathological response and safety profile for PDT in early-stage lesions larger than 1 cm (45)(46)(47)(48).…”

Section: Focused Reviewsmentioning

confidence: 82%

Photodynamic Therapy of Non–Small Cell Lung Cancer. Narrative Review and Future Directions

Battoo²,

et al. 2016

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an established treatment modality for non-small cell lung cancer. Phototoxicity, the primary adverse event, is expected to be minimized with the introduction of new photosensitizers that have shown promising results in phase I and II clinical studies. Early-stage and superficial endobronchial lesions less than 1 cm in thickness can be effectively treated with external light sources. Thicker lesions and peripheral lesions may be amenable to interstitial PDT, where the light is delivered intratumorally. The addition of PDT to standard-of-care surgery and chemotherapy can improve survival and outcomes in patients with pleural disease. Intraoperative PDT has shown promise in the treatment of non-small cell lung cancer with pleural spread. Recent preclinical and clinical data suggest that PDT can increase antitumor immunity. Crosslinking of signal transducer and activator of transcription-3 molecules is a reliable biomarker to quantify the photoreaction induced by PDT. Randomized studies are required to test the prognosis value of this biomarker, obtain approval for the new photosensitizers, and test the potential efficacy of interstitial and intraoperative PDT in the treatment of patients with non-small cell lung cancer.

show abstract

Section: Focused Reviewsmentioning

confidence: 82%

Photodynamic Therapy of Non–Small Cell Lung Cancer. Narrative Review and Future Directions

Battoo²,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…University of Southern California Medical School investigators reported a 97% complete response rate in 35 patients with predominantly primary NSCLC (n = 29) within the tracheobronchial tree, 41 and independent reports from Chinese investigators revealed 96% and 97% response rates in 21 patients with 24 bronchogenic carcinomas 42 and 54 patients with 69 bronchogenic carcinomas, 43 respectively.…”

Section: Non-small Cell Lung Cancermentioning

confidence: 98%

Photodynamic Therapy for Lung Cancer and Malignant Pleural Mesothelioma

Simone

Cengel

2014

Seminars in Oncology

101

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen (1O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic malignancies. For early-stage non-small cell lung cancer (NSCLC), PDT is primarily employed as an endobronchial therapy to definitively treat endobronchial or roentgenographically occult tumors. Similarly, patients with multiple primary lung cancers may be definitively treated with PDT. For advanced or metastatic NSCLC and small cell lung cancer (SCLC), PDT is primarily employed to palliate symptoms from obstructing endobronchial lesions causing airway compromise or hemoptysis. PDT can be used in advanced NSCLC to attempt to increase operability or to reduce the extent of operation required, and selectively to treat pleural dissemination intraoperatively following macroscopically complete surgical resection. Intraoperative PDT can be safely combined with macroscopically complete surgical resection and other treatment modalities for malignant pleural mesothelioma (MPM) to improve local control and prolong survival. This report reviews the mechanism of and rationale for using PDT to treat thoracic malignancies, details prospective and major retrospectives studies of PDT to treat NSCLC, SCLC, and MPM, and describes improvements in and future roles and directions of PDT.

show abstract

“…Several PDT phase II and phase III studies have been published [26][27][28][29][30][31][32][33]. In general, they all showed that recanalization of the tracheobronchial tree can be achieved, irrespective of the previous treatments given to the patients.…”

Section: Clinical Resultsmentioning

confidence: 99%

Photodynamic Therapy in Advanced Tracheobronchial Cancers

Sutedja

1999

Diagnostic and Therapeutic Endoscopy

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been introduced in the early eighties for treating patients with malignancies in the tracheobronchial tract. After intravenous injection of the photosensitizers, the tumor area in the tracheobronchial tree is illuminated bronchoscopically using a laser fiber to transmit light of a specific wavelength during the procedure. Secondary tissue necrosis ensues, because of the thrombosis of the tumor vasculature leading to late tissue hypoxia. Ample data have shown that PDT is effective to obtain full depth tissue necrosis with relative sparing of the normal tissue. Local tumor control can be achieved. Competitive endoscopic techniques such as lasers and electrocautery are applicable to debulk tumor in a less selective but more immediate manner. Skin photosensitivity is a potential morbidity of PDT, especially in using the first generation photosensitizers. This limits its palliative potential. More selective and more phototoxic sensitizers in combination with the use of portable diode laser, may improve the clinical usefulness of PDT in the management of lung cancer patients. However, cost-effectiveness studies comparing PDT and other local bronchoscopic treatment modalities such as thermal lasers, electrocautery, cryotherapy, brachytherapy, whether or not in addition to external radiotherapy and chemotherapy, should be conducted to define its definite role in the palliative treatment of advanced obstructive bronchial cancers.

show abstract

Application of hematoporphyrin derivative and laser‐induced photodynamical reaction in the treatment of lung cancer: A preliminary report on 21 cases

Cited by 20 publications

References 8 publications

Photodynamic Therapy of Non–Small Cell Lung Cancer. Narrative Review and Future Directions

Photodynamic Therapy of Non–Small Cell Lung Cancer. Narrative Review and Future Directions

Photodynamic Therapy for Lung Cancer and Malignant Pleural Mesothelioma

Photodynamic Therapy in Advanced Tracheobronchial Cancers

Contact Info

Product

Resources

About